Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'

Ann Rheum Dis. 2021 Oct;80(10):e162. doi: 10.1136/annrheumdis-2021-220756. Epub 2021 Jul 16.

Timm H Westhoff¹, Felix S Seibert¹, Moritz Anft^{2

3}, Arturo Blazquez-Navarro^{2

3

4}, Sarah Skrzypczyk^{2

3}, Adrian Doevelaar¹, Bodo Hölzer¹, Krystallenia Paniskaki⁵, Sebastian Dolff⁵, Benjamin Wilde⁶, Oliver Witzke⁶, Juergen Braun⁷, Ulrik Stervbo^{2

3

4}, Nina Babel^{8

3

4}

¹ Medical Department I, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany.
² Immundiagnostik, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany.
³ Center for Translational Medicine, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany.
⁴ Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
⁵ Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
⁶ Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
⁷ Rheumazentrum Ruhrgebiet, University Hospital of the Ruhr University Bochum, Herne, Germany.
⁸ Immundiagnostik, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany nina.babel@elisabethgruppe.de.

No abstract available

Keywords: Covid-19; rituximab; vaccination.

Publication types